Glaucoma 360 is a series of three days of annual events uniting research, industry, and philanthropy to prevent vision loss from glaucoma and speed the cure.
Join them at Glaucoma Research Foundation’s 11th annual New Horizons Forum for a sneak preview of the future — and the chance to influence next-generation care for this leading cause of blindness.
This symposium for clinicians highlights the latest advances in glaucoma management, medications and surgical technique.
In recent years, care has been revolutionized by novel devices that were once unimaginable.
Stents that lower eye pressure and deliver medications, surgical lasers, telemedicine tools that give patients a bigger role in their own health — now that innovations like these have raised the bar for glaucoma care, what’s next?
This year’s oneof-a-kind Glaucoma 360 New Horizons Forum will explore that question from many perspectives through sessions dedicated to new devices, telemedicine and more.
New Horizons in Devices Session co-moderators Inder Paul Singh, MD, and Barbara Wirostko, MD, FARVO — clinicians as well as innovators — are experienced in the development of new devices that protect and preserve vision.
President of The Eye Centers of Racine and Kenosha, Dr. Singh was an early adopter of and laser-assisted procedures and is currently engaged in several industry-sponsored studies.
An expert in drug-device development and a longtime eye-care entrepreneur, Dr. Wirostko is an Adjunct Professor of Ophthalmology and Biomedical Engineering at the University of Utah and is Co-founder and Chief Medical Officer of Qlaris Bio Inc.
This year’s forum also includes an all-industry panel on glaucoma devices, co-moderated by , and .
Drs. Bicket and Katz will lead a discussion with industry leaders covering everything from emerging diagnosis and care technologies, to healthcare policy, to the latest FDA evaluation criteria for new drugs and devices.
Presentations by emerging companies are always a highlight of the New Horizons Forum. Participants this year include Neurotech Pharmaceuticals, Inc. During a session dedicated to vision restoration, the company will provide an update on its sustained release cell-based delivery device, which targets the back of the eye.
Additional topics of discussion during the meeting will likely include the growing interest from Google, Apple, and other technology companies that view the eye as a platform for the diagnosis and treatment of other diseases.
As new devices and novel technologies continue to emerge, reimbursement will be another important issue for consideration at Glaucoma 360. To view the preliminary agenda and register for this year’s in-person/online New Horizons Forum visit